下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

CB Scientific, Inc. Announces Intent to Convene a Special Meeting of the Stockholders
CB Science,Inc.宣布打算召开股东特别大会

Accesswire ·  {{timeTz}}

Agenda to include matters necessary to better position the company for anticipated growth and development

议程包括更好地定位公司以实现预期增长和发展所需的事项

ESCONDIDO, CA / ACCESSWIRE / November 30, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") has announced it will convene a Special Stockholder Meeting in order to gain approval to implement a number of significant enhancements which management believes will better position CBSC to attain its stated business objectives. As previously disclosed, the Company is actively expanding its market awareness throughout Southeast Asia, especially including China, Malaysia, Thailand, Indonesia, and Singapore.

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2021年11月30日世邦魏理仕科技公司。亚洲网加利福尼亚州圣何塞4月18日电美国场外交易市场交易代码:CBSC)(以下简称“CBSC”或“公司”)宣布,它将召开特别股东大会,以便获得批准实施一些重大改进措施,管理层认为这些措施将使CBSC公司更好地实现其所陈述的业务目标。正如之前披露的那样,该公司正在积极扩大其在整个东南亚地区的市场知名度,特别是包括中国、马来西亚、泰国、印度尼西亚和新加坡。

"Based on recent progress, our leadership team concluded that the demonstrable progress achieved in key Asian markets, coupled with our recent application to up list to the OTCQB® Venture Market, has created sufficient traction for us to take action to better align the Company for the future success," said Paul Danner, Chairman of CBSC. "Specifically, we plan to seek shareholder approval to implement a corporate name change which more accurately describes our business direction and future growth potential, relocate our corporate domicile to a state which provides superior tax laws and corporate regulations, increase the number of our authorized common shares to facilitate essential fundraising aspirations, ratify the Company's 2021 Omnibus Stock Incentive Plan which we require to recruit and retain the best possible industry talent, as well as certain other actions necessary to properly position us for a potential listing on the Nasdaq exchange at some point in the future."

CBSC董事长保罗·丹纳(Paul Danner)表示:“根据最近的进展,我们的领导团队得出结论,在主要亚洲市场取得的明显进展,加上我们最近申请在OTCQB®创业板市场上市,已经为我们创造了足够的牵引力,使我们能够采取行动,更好地协调公司,为未来的成功而努力,”CBSC董事长保罗·丹纳(Paul Danner)说。具体地说,我们计划寻求股东批准,以实施更准确地描述我们的业务方向和未来增长潜力的公司名称更改,将我们的公司注册地迁往一个提供优越税法和公司法规的州,增加我们授权的普通股数量,以促进必要的筹资愿望,批准公司的2021年综合股票激励计划,这是我们招募和留住尽可能好的行业人才所需的,以及某些其他必要的行动,以使我们为未来某个时候在纳斯达克交易所上市做好适当的定位。“

The specific date and time of the Special Stockholder Meeting should be announced within a matter of weeks and will provide requisite notice pursuant to applicable laws, as well as the Company's current Bylaws and Certificate of Incorporation.

股东特别大会的具体日期和时间应在几周内公布,并将根据适用法律以及公司现行的章程和公司注册证书提供必要的通知。

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,使其股东、行业参与者和公开市场随时了解情况。

About CB Scientific, Inc.

关于CB Science,Inc.

CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

CB Science,Inc.通过其国内和国际子公司,在非侵入性非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件以及适用于iOS和Android平台的智能手机应用程序为有心律异常风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:

公司联系信息:

Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

电话:(888)225-0870
电子邮件:General Queries:info@cbSciences ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com
关注CBSC:Twitter、Facebook、Instagram、LinkedIn、YouTube和时事通讯

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

这一信息披露可能包含“1995年私人证券诉讼法案”所涵盖的前瞻性陈述。这些前瞻性陈述涉及推出或增强我们的服务和产品的计划和时间,有关未来市场状况、供需状况的陈述,以及本新闻稿中包含的其他预期、意图和计划,这些都不是历史事实,涉及风险和不确定因素。我们对未来收入的预期取决于我们开发和供应产品和服务的能力,这些产品和服务可能不是我们今天生产的,而且符合规定的规格。在本新闻稿中使用的“计划”、“预期”、“相信”以及类似的表述通常代表前瞻性陈述。这些声明反映了我们目前的期望。它们受到许多风险和不确定性的影响,包括但不限于技术的变化和无处不在的市场的变化。本新闻稿包括1933年“证券法”第27A节和1934年“证券法”第27E节的含义内的前瞻性陈述。本新闻稿中包含的非历史事实的陈述可能被视为前瞻性陈述。投资者需要注意的是,前瞻性陈述本质上是不确定的。由于某些风险和不确定因素,包括但不限于获得融资以及监管机构和股东对预期行动的批准的能力,实际业绩和结果可能与本文预测或建议的大不相同。

SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部